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Abstract
Background: Gender-based clinical differences are increasingly being identified as having significant influence on the
outcomes of patients with cardiovascular disease (CVD), including atrial fibrillation (AF).
Objective: To perform detailed clinical phenotyping on a cohort of hospitalised patients with chronic forms of AF to
understand if gender-based differences exist in the clinical presentation, thrombo-embolic risk and therapeutic
management of high risk patients hospitalised with chronic AF.
Methods: We are undertaking the Standard versus Atrial Fibrillation spEcific managemenT studY (SAFETY) - a multi-centre,
randomised controlled trial of an AF-specific management intervention versus usual care. Extensive baseline profiling of
recruited patients was undertaken to identify gender-specific differences for risk delineation.
Results: We screened 2,438 patients with AF and recruited 335 into SAFETY. Of these, 48.1% were women who were, on
average, 5 years older than their male counterparts. Women and men displayed divergent antecedent profiles, with women
having a higher thrombo-embolic risk but being prescribed similar treatment regimens. More women than men presented
to hospital with co-morbid thyroid dysfunction, depression, renal impairment and obesity. In contrast, more men presented
with coronary artery disease (CAD) and/or chronic obstructive pulmonary disease (COPD). Even when data was age-
adjusted, women were more likely to live alone (odds ratio [OR] 2.33; 95% confidence interval [CI] 1.47 to 3.69), have non-
tertiary education (OR 2.69; 95% CI 1.61 to 4.48) and be symptomatic (OR 1.93; 95% CI 1.06 to 3.52).
Conclusion: Health care providers should be cognisant of gender-specific differences in an attempt to individualise and,
hence, optimise the management of patients with chronic AF and reduce potential morbidity and mortality.
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Combating cardiovascular disease (CVD) in women, in all its
forms, represents an ongoing challenge [1] – from acknowledging
its wider impact from a population burden perspective (it remains
the single largest cause of death in women [1]) to formulating a
robust evidence-base for those affected. In both low-to-middle
[2,3] and high-income countries [3], the natural history of CVD
and age profile of affected women are typically different from their
male counterparts. This requires careful interpretation of key
clinical trials of new treatment strategies where women are almost
always in the minority [4,5]. Underlying gender-based differences
in the pattern and outcomes of CVD presentations are complex;
ranging from intrinsic drivers such as anatomic, physiological and
genetic factors, to differences in health behaviours, delays in
recognising and responding to symptoms, to critical health care
factors such as under-utilisation of gold-standard diagnostic tests
and treatments [6–8]. The current description of ‘‘typical’’ cardiac
symptoms is based primarily on white, middle-aged men and has
contributed to misconceptions in clinicians and lay individuals,
leading to inaccurate diagnosis and a delay in women seeking
treatment [9].
The conundrum of ensuring gender-based equity in outcomes is
becoming increasingly evident in relation to atrial fibrillation (AF).
Predicted to be the next CVD-related epidemic due to the
progressive ageing of the population and successful treatment of
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many of its antecedents, it is the most common cardiac arrhythmia
observed in clinical practice and accounts for approximately one
third of hospitalisations for all arrhythmias [10]. With a current
overall population prevalence of 2% to 3%, age-adjusted
prevalence rates are higher in males than females [10]. However,
the absolute number of women with AF exceeds that of men due
to their greater longevity [11,12]. Indeed, after 75 years of age (the
median age of AF diagnosis) approximately 60% of individuals
with AF are women [13]. Known clinically relevant differences
between women and men with AF currently relate only to the
prevalence, presentation and outcomes [14–17]. However, funda-
mental biological differences between women and men relating to
the underlying pathogenesis of AF have only just begun to be
elucidated.
Study aims
Consistent with the development of chronic heart failure (CHF)
management programs to support the application of gold-standard
therapeutics, with more equitable recruitment of women into key
clinical trials of the same [4], we are applying a systematic
approach to risk delineation and optimising management of
hospitalised patients with chronic forms of AF. As such, we are
undertaking the Standard versus Atrial Fibrillation spEcific
managemenT studY (SAFETY) [18]. We prospectively hypothe-
sised that gender-based differences would exist in the clinical
presentation, thrombo-embolic risk and therapeutic management
within the cohort of high risk patients hospitalised with a diagnosis
of chronic AF screened for and subsequently recruited into
SAFETY. We further hypothesised that subject to detailed clinical
phenotyping, these differences would have important clinical
implications in respect to disease management requirements.
Methods
Ethics statement
Ethics approval was obtained from the Central Northern
Adelaide Health Service Ethics of Human Research Committee,
Metro South Health Service District Human Research Ethics
Committee, Melbourne Health Human Research Ethics Com-
mittee, Western Health Office for Research and the ACT Health
Directorate Human Research Ethics Committee. Written in-
formed consent was obtained from each study participant prior to
study procedures being conducted.
Study setting
The overall purpose and design of SAFETY has been described
in greater detail previously [18]. In brief, 335 hospital in-patients
with chronic forms of AF were recruited from three tertiary
hospitals in Australia. All were subject to comprehensive baseline
profiling. Patients were randomised to either usual post-discharge
care or a home-based, multidisciplinary, AF-specific intervention
designed to reduce morbidity and mortality.
Study participants
A systematic screening program to identify eligible inpatients
was conducted at each participating hospital. Patients were
approached for recruitment if they were English-speaking, had a
documented diagnosis of recurrent paroxysmal (i.e. recurrent
episodes by history as documented on ECG), persistent or
permanent AF; were living independently in the community or
their own home post-hospitalisation; and were able and willing to
provide written informed consent to participate. Patients were
excluded if they were aged less than 45 years, had a primary
diagnosis of valvular heart disease, were scheduled for catheter
ablation of their AF, had pre-existing CHF as evidenced by the
combination of symptoms indicative of NYHA Class III-IV with a
documented left ventricular ejection fraction (LVEF) less than
45%, or had a transient form of AF. Patients with dementia, as
assessed on routine evaluations conducted by hospital clinical
teams, were also excluded as were patients who were too unwell at
the time when testing was attempted.
Data Collection
Baseline profiling
Comprehensive profiling of each patient subsequently enrolled
in SAFETY involved the collection of basic socio-demographic,
past medical history and current admission data. In addition,
questionnaires were administered at the time of recruitment
(wherever feasible) to assess lifestyle (i.e. cigarette and alcohol
consumption, exercise and sleep habits), health-related quality-of-
life (HRQoL – via EuroQol 5-dimension scale [EQ-5D] [19] and
Short Form 12 [SF-12] [20]), depression status (via the ARROLL
[21] 6 Centre for Epidemiological Studies Depression Scale
[CES-D] [22]) and cognitive function (via the Montreal Cognitive
Assessment [MoCA] [23]). Furthermore, a comprehensive profile
of each patient’s experiences with AF was derived, including sub-
type classification, patient-reported symptoms, patient-reported
triggers, patient awareness (of AF episodes, symptoms and
triggers), previous and current treatment plans. The CHA2DS2-
VASc score was used as a risk stratification tool to assess
requirements for antithrombotic therapy [24]. For the current
research, the CHA2DS2-VASc score was scored from 0-8 (not 0–9
as is the norm) due to the exclusion of patients with chronic heart
failure. All questionnaire data were collected prospectively during
face-to-face semi-structured interview by trained personnel
according to standardised criteria. Self-reported AF profile data
was collected utilising an investigator designed interview guide that
specifically asked about symptoms experienced and triggers
associated with episodes.
Statistical analyses
Where appropriate, descriptive values are presented as mean (6
standard deviation [SD]) for continuous variables or a proportion
for categorical variables. Differences between women and men
were assessed using the chi-square (X2) test for dichotomous
variables and independent t-test for normally distributed contin-
uous variables. Age-adjusted comparisons of the socio-demo-
graphic, risk and clinical profile of patients were examined with a
simple regression model. Only statistically significant odds ratios
(ORs) are presented. Data were analysed using SPSS, V.20. A
probability value of p,0.05 (two-sided) was considered statistically
significant.
Results
Patient screening and recruitment
Figure 1 shows the profile of screened and recruited patients
according to gender. Overall, of the 2,438 patients with AF (as a
primary or secondary diagnosis) screened for entry into SAFETY
across the three hospital study sites, n= 335 (13.7%) were enrolled.
Of these, 1,167 (47.9%) were women and 1,271 (52.1%) were
men. The mean age of these patients who presented to hospital
with AF was 75 years 613 years. Women presented, on average, 4
years older than men (77 years 613 years versus 73 years 613
years, respectively).
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Socio-demographic profile
As shown in Table 1, 161 (48.1%) recruited patients were
women aged, on average, 5 years older than their male
counterparts. Over half of these women were aged 75 years or
more compared to just over a third of men in the same age group.
In addition, more than half of female patients were currently living
alone (as a result of being divorced/separated [4.8%], having been
widowed [17.6%] or never being married [2.1%]; p,0.001).
Further, the proportion of women who had formal education at a
tertiary level was less than half that of male participants.
AF antecedents
As shown in Table 1, women demonstrated a higher mean
body mass index (BMI) than men reflecting that, on average,
women were classified as ‘‘obese’’ and men as ‘‘overweight’’. Just
over one third of women undertook the recommended levels
(specifically for older individuals) of exercise in Australia [25]
compared to over half of their male counterparts. Only a minority
of women (6%) consumed alcohol at ‘‘high risk’’ levels (considered
more than two standard drinks on any one occasion [26]),
compared to over a quarter of male patients. A similar proportion
of women reported currently smoking cigarettes. Over double the
proportion of men compared to women reported current cigarette
smoking. Self-reported average sleep quality was ‘‘poor’’ according
to one third of the female patients; however, the same reports were
made by 22% of their male counterparts (p= 0.037).
AF-specific profile
Women and men showed a similar pattern of basic AF
characteristics (Table 1). Future thrombo-embolic risk, as
calculated via the CHA2DS2-VASc score was significantly higher
in women than men.
Co-morbidity profile
Gender-based differences in the co-morbidity of the study
cohort were also evident (Table 1). Both concomitant coronary
artery disease (CAD) and chronic obstructive pulmonary disease
(COPD) was more common in men (41.4% versus 24.8% and
20.1% versus 11.2%, respectively). Conversely, it was significantly
more common for women to present with co-morbid thyroid
dysfunction (previously ruled out as the cause of AF), depression,
renal impairment and obesity. Women had more preserved
cardiac function as reflected by a higher mean LVEF than men
(61.4%610.3% versus 54.4%613.0%; p= 0.005). With respect to
HRQoL, the only difference was that women had more overall
physical limitations (as determined by a lower composite score of
the SF-12; p,0.001).
Figure 1. Flow chart of SAFETY recruitment stratified by gender.
doi:10.1371/journal.pone.0065795.g001
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(n =174) p value
Socio-demographic profile
Mean age (years) 74.0610.3 69.3611.6 p,0.001
$75 years 81 (50.3%) 64 (36.8%) p=0.013
Living alone (%) 82 (50.9%) 50 (28.7%) p,0.001
Tertiary level education obtained (%)* 30 (19.0%) 68 (40.7%) p,0.001
Employed in unskilled/semi-skilled occupation (%){ 89 (71.8%) 73 (48.0%) p,0.001
AF-specific profile
Paroxysmal AF diagnosis (%) 4 (2.5%) 9 (5.2%) p= 0.203
Persistent AF diagnosis (%) 140 (87.0%) 149 (85.6%) p= 0.725
Permanent AF diagnosis (%) 17 (10.6%) 16 (9.2%) p= 0.676
Rate Control (%) 102 (63.4%) 112 (64.4%) p= 0.847
Rhythm Control (%) 59 (36.6%) 62 (35.6%) p= 0.847
Mean CHA2DS2-VASc score 462 362 p,0.001
Antecedents
Mean HR on admission (bpm) 101634 97633 p= 0.268
Mean HR at discharge (bpm) 74615 75617 p= 0.883
Mean BMI (kg/m2)? 30.567.9 28.865.3 p=0.033
Mean Total serum cholesterol (mmol/L) 4.361.2 4.161.1 p= 0.097
At least 150 mins moderate intensity exercise per week (%)1 58 (36.7%) 95 (55.9%) p=0.001
‘‘High risk’’ alcohol intake (%)1 " 9 (5.9%) 41 (25.6%) p,0.001
‘‘Poor’’ sleep quality (%) 51 (32.3%) 37 (22.0%) p=0.037
Current cigarette smoker (%)1 12 (7.6%) 32 (18.8%) p=0.003
Co-morbidity profile
Hypertension (%) 123 (76.4%) 117 (67.2%) p= 0.063
CAD (%) 40 (24.8%) 72 (41.4%) p=0.001
Type 2 diabetes (%) 45 (28.0%) 51 (29.3%) p= 0.783
Stroke/Systemic Embolism/TIA (%) 21 (13.0%) 31 (17.8%) p= 0.228
COPD (%) 19 (11.8%) 35 (20.1%) p=0.039
Thyroid dysfunction (%) 18 (11.2%) 8 (4.6%) p=0.024
Depression (%) 56 (34.8%) 40 (23.0%) p=0.017
Renal Impairment (eGFR,60 mL/min/1.73 m2, %) 70 (43.8%) 47 (27.2%) p=0.002
Obesity (BMI $30 kg/m2, %)? 69 (49.6%) 59 (37.3%) p=0.033
Mean LVEF (%) 61.4%610.3% 54.4%613.0% p=0.005
Mean MoCA score 2364 2364 p= 0.828
Mean SF-12 HRQoL physical component score (PCS) 34.7611.5 40.6611.5 p,0.001
Mean SF-12 HRQoL mental component score (MCS) 49.3611.9 50.7610.8 p= 0.264
Mean EQ-5D HRQoL score 0.71660.202 0.75960.244 p= 0.084
Treatment profile
Beta Blocker (%) 77 (47.8%) 88 (50.6%) p= 0.615
Digoxin (%) 64 (39.8%) 53 (30.5%) p= 0.075
Anti-arrhythmic (%) 51 (31.7%) 50 (28.7%) p= 0.558
Diuretic (%) 84 (52.2%) 55 (31.6%) p,0.001
Warfarin (%) 87 (54.0%) 99 (56.9%) p= 0.599
Aspirin only (%) 75 (46.6%) 86 (49.4%) p= 0.603
Aspirin plus Clopidogrel (%) 29 (18.0%) 33 (19.0%) p= 0.822
Premature discontinuation of anti-thrombotic therapy (%) 40 (24.8%) 45 (25.9%) p= 0.831
*Assessed in n= 325 patients; { Assessed in n= 276 patients; ? Assessed in n= 297 patients; 1 Assessed in n= 328 patients; " defined as consumption of .2 standard
drinks on any occasion (on average).
AF = Atrial Fibrillation; CHA2DS2-VASc score definition: C = congestive heart failure/LV dysfunction (1 point), H = hypertension (even if treated; 1 point), A2= age $75
years (2 points), D= diabetes mellitus (1 point), S2= stroke/SE/TIA (2 points), V= vascular disease (1 point), A= age 65–74 years (1 point), Sc = sex category (female sex; 1
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Treatment profile
Nominated rate or rhythm control of underlying AF was similar
for men and women (approximately 64% for rate and 36% for
rhythm, p= 0.847 for both) and this was reflected in the most
commonly prescribed medications (beta blocker, digoxin or anti-
arrhythmic) to achieve therapeutic goals in AF. Despite increased
thrombo-embolic risk in women, there were no discernible
differences in anti-thrombotic use (warfarin, aspirin alone or in
combination with clopidogrel) between the sexes. When anti-
thrombotic therapy was further assessed, approximately 25% of
both sexes reported premature and permanent treatment discon-
tinuation due to, most commonly, a procedure requiring therapy
withdrawal (7.5% versus 12.1% for women versus men; p= 0.157),
their physician’s decision (6.2% versus 5.7%; p= 0.858) or a
bleeding episode (6.8% versus 4.0%; p= 0.255). Finally, it was
significantly more common for women to be prescribed diuretic
therapy than for men (52.2% versus 31.6%; p,0.001).
Symptom and trigger profile
There were gender-related differences present in AF symptoms
self-reported by patients. Of the more typical symptoms commonly
described by patients relating to the presence of AF (or rapid AF
for those with permanent AF), significantly more women than men
reported fatigue or lethargy (56.5% versus 44.3%; p= 0.025),
palpitations or ‘‘fluttering’’ (63.4% versus 38.5%; p,0.001) and
weakness (43.5% versus 29.9%; p= 0.010). Alternatively, no
gender-based differences were observed in respect to self-reported
triggers of AF (stress, overexertion, illness, medications or alcohol).
Age-adjusted comparisons of women and men
Figure 2 provides a summary of age-adjusted comparisons of
the demographic and clinical characteristics of women and men.
From a demographic perspective, women were more than twice as
likely to live alone and were nearly six times more likely to be a
widow. In addition, women were almost three times more likely to
have non-formal tertiary education and to have worked in an
unskilled/semi-skilled occupation (i.e. clerical/ administration/
community worker/ personal/ customer service/ labourer).
Clinically, women were approximately twice as likely to experi-
ence symptomatic AF (particularly palpitations, weakness and
fatigue), have a high thrombo-embolic risk (indicated by a
CHA2DS2-VASc score of 3 or more), be classified as obese and
have renal impairment, but no medical history of CAD or COPD.
Furthermore, stress was the most likely trigger of an episode of AF
(or rapid AF) in double the proportion of women to men. With
regard to lifestyle factors, women were almost 4.5 times more likely
to consume alcohol at ‘‘low risk’’ levels, twice as likely to be a non-
smoker but unlikely to undertake the recommended weekly levels
of exercise. From a treatment perspective, women were about 2.5
times more likely to be prescribed an anti-depressant than men
and twice as likely to be receiving diuretic therapy.
Discussion
Given parallel issues relating to high levels of morbidity and
mortality, there remains a paucity of studies examining the
potential impact of AF-specific management programs with the
potential to deliver equivalent improvements in health outcomes
similar to those applied to patients with CHF [4]. Like the seminal
trials of CHF management programs, there is the potential to
address critical gender imbalances in developing evidence-based
therapeutics; via the same pattern of recruiting older, more
complex and more gender-balanced study cohorts who more
accurately reflect real-world patient populations. With the notable
exception of the earliest report of AF-specific management from
our group [27], and the largest AF-specific management trial to
date (involving 712 patients) [28], SAFETY represents one of the
largest studies of its kind. In this detailed examination of the
SAFETY cohort from a gender-specific perspective, we can not
only confirm a more even balance of men and women consistent
with the broad epidemiology of AF that contrasts with key clinical
trials, but some important differences that will likely influence
individualised management. As represented by Figure 3, the
‘‘typical’’ demographic and clinical profile of female and male
patients in the SAFETY cohort (and by inference the wider AF
patient population) is markedly different. Of particular interest, in
our cohort, typically older women were more socially isolated and
less educated. While this is not surprising given the social history of
Australia (as with many other countries), these factors have
potentially important implications for disease-specific knowledge,
symptom recognition and seeking medical assistance. Further-
more, we have recently highlighted the critical importance of mild
cognitive impairment in older individuals with AF, recommending
systematic screening to determine those at risk and/or requiring
modification to any educational programs, although this applies
equally to women and men [29].
Our findings are consistent with those of other studies reporting
that women with AF were older, had a higher symptom burden,
had poorer HRQoL, were more likely to be treated with diuretics,
had an increased prevalence of hypertension, and that men with
AF had a higher prevalence of CAD [14–17].The Symptom
Mitigation in Atrial fibRillaTion (SMART) Study by Goli et al.
showed that patients with severe AF symptoms were more likely to
be female and less educated [30]. The current study provides an
extension to previous data by identifying additional socio-
demographic, lifestyle, clinical and therapeutic factors of potential
importance to longer-term health outcomes and individualised
management. When considering AF-specific management studies,
some potentially influential differences between the cohorts exist.
Age profiles of the nurse-led care and usual care cohorts of the AF-
Clinic study conducted by Hendriks et al. comprising 44.7% and
37.9% females, were 66613 years and 67612 years, respectively
[28]. Female and male patients in the current study were 7–8 years
and 2–3 years older than participants of AF-Clinic, respectively.
Furthermore, patients of the current research were high-risk,
hospitalised patients unlike the healthier participants recruited by
Hendriks et al. within primary care clinics [28].
point); HR = Heart Rate; bpm = beats per minute; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; BMI = Body Mass Index; HDL = High Density
Lipoprotein; LDL = Low Density Lipoprotein; CAD = Coronary Artery Disease; PVD = Peripheral Vascular Disease; TIA = Transient Ischaemic Attack; COPD = Chronic
Obstructive Pulmonary Disease; eGFR = estimated Glomerular Filtration Rate; LVEF = Left Ventricular Ejection Fraction; MoCA = Montreal Cognitive Assessment; SF-12
= Short Form 12 items questionnaire; HRQoL = Health-Related Quality of Life; PCS = Physical Composite Score; MCS = Mental Composite Score; EQ-5D = EuroQol
Five-Dimensional questionnaire; INR = International Normalised Ratio.
doi:10.1371/journal.pone.0065795.t001
Table 1. Cont.
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Common identification of gender-related diversity may poten-
tially reflect different pathways of development and/or promotion
of AF between the sexes. From the current data, it appears that the
pathway to AF in men is related to CAD and/or ischaemic heart
disease. However, for women, AF was more commonly associated
with co-morbid conditions (hypertension, obesity, thyroid and
renal dysfunction). It is also possible that women experience AF
differently to their male counterparts. Historically, oestrogen was
implicated as the cause of the gender-related diversity in CVD and
extensive observational data supported this theory. However,
recent prospective clinical trials have shown that oestrogen therapy
alone or in combination with progestin does not protect from
CVD or stroke and may even be harmful [31,32]. Electrophys-
iologic differences throughout the atrial tissue (e.g. in the atrial
effective refractory period) and hormonal differences are now
suggested as potential mechanisms [6]. More broadly, differences
in serum cholesterol, BMI and diabetes prevalence being
responsible for approximately 50% of the gender-related disparity
between women and men with CVD have also been described
[33]; a similar relationship could be assumed for AF. The
Figure 2. Age-adjusted differences in the profile of women (versus men) recruited into SAFETY.
doi:10.1371/journal.pone.0065795.g002
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prescription of evidence-based treatment strategies may also be
influenced by the gender of the presenting individual [6]. Here, we
have described the influence of gender on gold-standard anti-
thrombotic AF-treatment; women are at higher thrombo-embolic
risk, yet treatment regimens remain no different to those of men.
Further, women experience a greater symptom burden, indicating
that standards for rate (or rhythm) control may also show gender
inequality. It is also possible that the involved therapeutic regimens
required for AF management may be too complex to be optimised
for typically less educated women with a small (if existent) support
network.
The differences identified in the current research have
important clinical implications for the management of patients
with AF based on their gender. Utilising more specific factors to
formulate and deliver individualised disease management pro-
grams may enable improvement of clinical outcomes. A higher
symptom burden identified in women suggests the need for
increased education into symptom recognition and clinical impact,
ensuring that help is sought as early as possible before major
deterioration. To this end, design and delivery of educational
programs targeted at assisting patients to develop an inventory of
skills relating to when to seek medical attention is essential.
Women are at greater risk of AF-related complications due to
being older at presentation, more clinically complex and at greater
thrombo-embolic risk than their male counterparts within the
context of similar prescription and delivery of AF-specific
therapeutic regimens. Difficulty in interpreting the severity of
symptoms of acute coronary syndrome was shown to be most
predictive in female patients who delay seeking care [34].
Confusion in symptom identification, interpretation and percep-
tion and their vulnerability to heart disease by women and health
care professionals has led to a delay in seeking care for cardiac
problems that can reduce the success of treatment or prevent the
use of some interventions [35]. Increasing knowledge of different
patients’ experiences of AF would allow for education to be
adjusted accordingly with the ultimate aim of preventing
readmissions and longer-term morbidity and mortality.
Awareness of specific gender-related differences is critical when
applying disease management programs that include examining
the effectiveness of newly developed therapeutics for the medical
management of chronic diseases. As clinical trials inform the
advancement of clinical practice, it is useful to understand the
ready application of results from recent positive trials in patients
with AF to patients in ‘‘real world’’ clinical practice. Comparison
of ‘‘real world’’ AF patients with clinical trial cohorts shows that
clinical differences may have implications for balancing benefit
and risk when applying standardised therapies to high risk AF
patients. Differing from recent clinical trial cohorts, SAFETY is
most reflective of the true ratio of high risk women to men with AF
who present to hospital (see Table 2). It is likely that gender-based
differences in AF will be exacerbated in the next decade or more;
for example, in Australia it is predicted that there will be equal
Figure 3. Typical socio-demographic and risk profiles of women versus men with chronic AF in the SAFETY cohort.
doi:10.1371/journal.pone.0065795.g003
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numbers of females aged ,5 years as those .80 years (far
outnumbering equivalent aged men). Much research is still
required to complete the picture of the physiology behind
gender-specific differences in patients with AF; the current
research contributes somewhat to its elucidation. It will also be
important to learn if these differences extend beyond hospitalisa-
tion. Confirmation of gender-specific differences in patients with
chronic AF highlights a need to identify and accommodate
differences into disease management programs. Otherwise, clinical
outcomes may be compromised. Awareness of key gender-specific
differences in AF allows for formulation and delivery of a safer,
more effective and individualised approach to clinical manage-
ment with patient stratification into well-known risk groups.
There are a number of limitations that require comment.
Firstly, the respective cohorts of women and men analysed are
relatively small and focused only on those who are high risk and
have been hospitalised in Australia (with its hybrid universal
health/private health care system). Therefore, findings from the
current research may not be readily applicable to all women and
men with AF in different countries and health care settings.
Further, the cohort consists of those who are acutely ill, potentially
exaggerating clinical stability and affecting generalisability of the
findings. Exclusion of non-English speaking individuals into the
study may have introduced selection bias, although English
competency is necessary for comprehensive understanding of the
many questionnaires administered. Furthermore, the often chaotic
acute clinical setting under which the initial comprehensive
assessment was conducted in addition to the patients’ altered
health state may not represent an ideal testing situation. Despite
the selection of a ‘‘real world’’ cohort, we cannot discount the
possibility of bias in study selection (perhaps still under-represent-
ing females despite screening data) and these data may not readily
apply to other hospitalised cohorts.
Whether observed differences in this cohort (particularly in
respect to treatment) translate to differential health outcomes is still
unknown (study follow-up will be complete in late 2013). Despite
these limitations, these data have important clinical implications
for the post-discharge management of patients with chronic AF.
Conclusion
Gender differences identified in high risk individuals hospital-
ised with chronic AF must be recognised as valid stratifying
features for the treatment and prevention of poorer health
outcomes in this patient group. Health care providers should be
cognisant of these defining features in an attempt to individualise
and, hence, optimise the management of patients with chronic AF
and reduce potential morbidity and mortality.
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